Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 TORRENT PHARMA   MYLAN
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-23
MYLAN
Dec-18
TORRENT PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,7233,967-   
Low Rs1,2432,184-   
Sales per share (Unadj.) Rs284.21,825.4-  
Earnings per share (Unadj.) Rs36.849.6-  
Cash flow per share (Unadj.) Rs57.7391.3-  
Dividends per share (Unadj.) Rs22.000-  
Avg Dividend yield %1.50-  
Book value per share (Unadj.) Rs183.11,974.7-  
Shares outstanding (eoy) m338.45514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x5.21.7 309.6%   
Avg P/E ratio x40.362.0 64.9%  
P/CF ratio (eoy) x25.77.9 327.2%  
Price / Book Value ratio x8.11.6 519.9%  
Dividend payout %59.80-   
Avg Mkt Cap Rs m501,7791,582,214 31.7%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m16,7770-   
Avg. sales/employee Rs Th026,833.1-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.6-  
INCOME DATA
Net Sales Rs m96,202939,158 10.2%  
Other income Rs m6320-   
Total revenues Rs m96,834939,158 10.3%   
Gross profit Rs m28,240243,019 11.6%  
Depreciation Rs m7,066175,847 4.0%   
Interest Rs m3,33445,170 7.4%   
Profit before tax Rs m18,47222,002 84.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,019-3,500 -172.0%   
Profit after tax Rs m12,45225,502 48.8%  
Gross profit margin %29.425.9 113.4%  
Effective tax rate %32.6-15.9 -204.8%   
Net profit margin %12.92.7 476.7%  
BALANCE SHEET DATA
Current assets Rs m53,137524,425 10.1%   
Current liabilities Rs m54,473382,364 14.2%   
Net working cap to sales %-1.415.1 -9.2%  
Current ratio x1.01.4 71.1%  
Inventory Days Days1584 18.5%  
Debtors Days Days793 7.9%  
Net fixed assets Rs m91,390182,181 50.2%   
Share capital Rs m1,692500 338.4%   
"Free" reserves Rs m60,2880-   
Net worth Rs m61,9811,015,998 6.1%   
Long term debt Rs m24,9621,096,588 2.3%   
Total assets Rs m144,6822,725,301 5.3%  
Interest coverage x6.51.5 439.8%   
Debt to equity ratio x0.41.1 37.3%  
Sales to assets ratio x0.70.3 192.9%   
Return on assets %10.92.6 420.8%  
Return on equity %20.12.5 800.4%  
Return on capital %25.13.2 788.8%  
Exports to sales %21.80-   
Imports to sales %00-   
Net fx Rs m17,2590-   
CASH FLOW
From Operations Rs m23,681195,157 12.1%  
From Investments Rs m-24,153-100,875 23.9%  
From Financial Activity Rs m774-90,916 -0.9%  
Net Cashflow Rs m1,1011,617 68.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare TORRENT PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare TORRENT PHARMA With: MANGALAM DRUGS  GUJ.TERC LAB  BANDARAM PHARMA PACKTECH  JAGSON PHAR  PARMAX PHARMA  



Today's Market

Sensex Today Rallies 550 Points| Nifty Tops 22,250 | Power Stocks Shine Sensex Today Rallies 550 Points| Nifty Tops 22,250 | Power Stocks Shine(10:30 am)

Asian markets traded lower, while the US stock indices ended higher overnight with the S&P 500 hitting a record closing high ahead of key economic data.